FoRx Therapeutics AG appoints Jens Würthner as Chief Medical Officer
Basel, Switzerland, 26 February 2025 – FoRx Therapeutics AG, a company committed to discovering and developing innovative drugs targeting cancer-relevant DNA Damage Response (DDR) pathways, announced today the appointment of Jens Würthner, MD, PhD, as Chief Medical Officer.
Jens has 20+ years of clinical development expertise with a track record that includes the successful progression of drug candidates from Phase I initiation to market approval. He has led clinical development programs at large pharmaceutical companies, namely Novartis, GlaxoSmithKline and AstraZeneca, as well as at biotech companies, such as ADC Therapeutics. At ADC Therapeutics, Jens oversaw all aspects of clinical development of several successful programs, including loncastuximab teserine (Zynlonta). Before that, he was Lead Clinical Program Leader at Novartis, where he was responsible for progressing small molecule compounds and a monoclonal antibody through multiple clinical trials. Jens is an author of numerous publications and serves as visiting senior lecturer at King’s College London, Faculty of Life Sciences & Medicine. He is board-certified in Medical Microbiology and Virology (Germany) as well as Pharmaceutical Medicine (UK). Jens joins us from Scenic Biotech, where he has been building the translational and clinical teams for the oncology and rare disease franchise in preparation for first-in-human studies.
Jens holds an MD and a PhD from the University of Hamburg and completed a postdoctoral fellowship at the Laboratory of Cell Regulation & Carcinogenesis, National Cancer Institute, National Institutes of Health in Bethesda, Maryland.
About FoRx Therapeutics
FoRx Therapeutics is a biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress pathways activated in cancer. Drawing on discoveries by Prof. Thanos Halazonetis and Dr. Sotirios Sotiriou, FoRx was co-founded in 2019 with M Ventures, Novartis Venture Fund and Omega Funds along with Pfizer Ventures, the venture capital arm of Pfizer Inc. (NYSE: PFE), and LSP (Life Science Partners, now EQT Life Sciences). For more information, visit www.forxtherapeutics.com